Cadrenal Therapeutics, Inc. (CVKD) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
11/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseCVKD / S&P -34.77% / 15.20% |
LoseCVKD / S&P CVKD unavailable / 15.00% |
LoseCVKD / S&P -49.12% / 50.40% |
| 2026-Q10/3 |
LoseCVKD / S&P -24.48% / -4.33% |
LoseCVKD / S&P CVKD unavailable / 11.30% |
LoseCVKD / S&P -43.70% / 27.70% |
| 2025-Q40/3 |
LoseCVKD / S&P -50.98% / 2.65% |
LoseCVKD / S&P CVKD unavailable / 9.00% |
LoseCVKD / S&P -29.46% / 13.40% |
| 2025-Q32/3 |
WinCVKD / S&P 14.77% / 8.12% |
LoseCVKD / S&P CVKD unavailable / 4.61% |
WinCVKD / S&P 30.55% / 13.45% |
| 2025-Q21/3 |
LoseCVKD / S&P -31.65% / 10.94% |
LoseCVKD / S&P CVKD unavailable / 4.83% |
WinCVKD / S&P 73.83% / 10.63% |
| 2025-Q12/3 |
WinCVKD / S&P 21.67% / -4.27% |
LoseCVKD / S&P CVKD unavailable / 4.98% |
WinCVKD / S&P 194.99% / 10.57% |
| 2024-Q42/3 |
WinCVKD / S&P 6.15% / 2.41% |
LoseCVKD / S&P CVKD unavailable / 5.25% |
WinCVKD / S&P 309.96% / 6.15% |
| 2024-Q32/3 |
WinCVKD / S&P 93.62% / 5.89% |
LoseCVKD / S&P CVKD unavailable / 5.89% |
WinCVKD / S&P 203.62% / 6.11% |
| 2024-Q21/3 |
LoseCVKD / S&P -22.95% / 4.28% |
LoseCVKD / S&P CVKD unavailable / 5.38% |
WinCVKD / S&P 316.54% / 5.12% |
| 2024-Q11/3 |
LoseCVKD / S&P -17.57% / 10.56% |
LoseCVKD / S&P CVKD unavailable / 5.71% |
WinCVKD / S&P 189.74% / 5.59% |
| 2023-Q40/3 |
LoseCVKD / S&P 8.82% / 11.69% |
LoseCVKD / S&P CVKD unavailable / 6.81% |
LoseCVKD / S&P CVKD unavailable / 7.78% |
| 2023-Q30/3 |
LoseCVKD / S&P -54.97% / -3.27% |
LoseCVKD / S&P CVKD unavailable / 7.52% |
LoseCVKD / S&P CVKD unavailable / -5.03% |
| 2023-Q20/3 |
LoseCVKD / S&P 7.09% / 8.74% |
LoseCVKD / S&P CVKD unavailable / 9.50% |
LoseCVKD / S&P CVKD unavailable / -8.57% |
| 2023-Q10/3 |
LoseCVKD / S&P CVKD unavailable / 7.50% |
LoseCVKD / S&P CVKD unavailable / 10.77% |
LoseCVKD / S&P CVKD unavailable / -15.69% |
| 2022-Q40/3 |
LoseCVKD / S&P CVKD unavailable / 7.56% |
LoseCVKD / S&P CVKD unavailable / 11.88% |
LoseCVKD / S&P CVKD unavailable / -17.99% |
| 2022-Q30/3 |
LoseCVKD / S&P CVKD unavailable / -4.88% |
LoseCVKD / S&P CVKD unavailable / 13.47% |
LoseCVKD / S&P CVKD unavailable / -1.41% |
| 2022-Q20/3 |
LoseCVKD / S&P CVKD unavailable / -16.10% |
LoseCVKD / S&P CVKD unavailable / 13.71% |
LoseCVKD / S&P CVKD unavailable / 11.04% |
| 2022-Q10/3 |
LoseCVKD / S&P CVKD unavailable / -4.60% |
LoseCVKD / S&P CVKD unavailable / 15.97% |
LoseCVKD / S&P CVKD unavailable / 42.23% |
| 2021-Q40/3 |
LoseCVKD / S&P CVKD unavailable / 11.03% |
LoseCVKD / S&P CVKD unavailable / 15.00% |
LoseCVKD / S&P CVKD unavailable / 96.40% |
| 2021-Q30/3 |
LoseCVKD / S&P CVKD unavailable / 0.58% |
LoseCVKD / S&P CVKD unavailable / 10.77% |
LoseCVKD / S&P CVKD unavailable / 69.42% |
| 2021-Q20/3 |
LoseCVKD / S&P CVKD unavailable / 8.55% |
LoseCVKD / S&P CVKD unavailable / 6.58% |
LoseCVKD / S&P CVKD unavailable / 51.81% |
| 2021-Q10/3 |
LoseCVKD / S&P CVKD unavailable / 6.17% |
LoseCVKD / S&P CVKD unavailable / -1.06% |
LoseCVKD / S&P CVKD unavailable / 7.39% |
| 2020-Q40/3 |
LoseCVKD / S&P CVKD unavailable / 12.15% |
LoseCVKD / S&P CVKD unavailable / -3.72% |
LoseCVKD / S&P CVKD unavailable / -33.42% |
| 2020-Q30/3 |
LoseCVKD / S&P CVKD unavailable / 8.93% |
LoseCVKD / S&P CVKD unavailable / -2.04% |
LoseCVKD / S&P CVKD unavailable / -27.10% |
| 2020-Q20/3 |
LoseCVKD / S&P CVKD unavailable / 20.54% |
LoseCVKD / S&P CVKD unavailable / -0.46% |
LoseCVKD / S&P CVKD unavailable / -27.11% |
| 2020-Q10/3 |
LoseCVKD / S&P CVKD unavailable / -19.60% |
LoseCVKD / S&P CVKD unavailable / 3.47% |
LoseCVKD / S&P CVKD unavailable / -14.75% |
| 2019-Q40/3 |
LoseCVKD / S&P CVKD unavailable / 9.07% |
LoseCVKD / S&P CVKD unavailable / 5.36% |
LoseCVKD / S&P CVKD unavailable / 2.99% |
| 2019-Q30/3 |
LoseCVKD / S&P CVKD unavailable / 1.70% |
LoseCVKD / S&P CVKD unavailable / 5.02% |
LoseCVKD / S&P CVKD unavailable / 0.21% |
| 2019-Q20/3 |
LoseCVKD / S&P CVKD unavailable / 4.30% |
LoseCVKD / S&P CVKD unavailable / 6.64% |
LoseCVKD / S&P CVKD unavailable / 8.65% |
| 2019-Q10/3 |
LoseCVKD / S&P CVKD unavailable / 13.65% |
LoseCVKD / S&P CVKD unavailable / 8.12% |
LoseCVKD / S&P CVKD unavailable / 14.29% |
| 2018-Q40/3 |
LoseCVKD / S&P CVKD unavailable / -13.52% |
LoseCVKD / S&P CVKD unavailable / 9.05% |
LoseCVKD / S&P CVKD unavailable / 18.23% |
| 2018-Q30/3 |
LoseCVKD / S&P CVKD unavailable / 7.71% |
LoseCVKD / S&P CVKD unavailable / 10.21% |
LoseCVKD / S&P CVKD unavailable / 19.06% |
| 2018-Q20/3 |
LoseCVKD / S&P CVKD unavailable / 3.43% |
LoseCVKD / S&P CVKD unavailable / 9.03% |
LoseCVKD / S&P CVKD unavailable / 14.46% |
| 2018-Q10/3 |
LoseCVKD / S&P CVKD unavailable / -0.76% |
LoseCVKD / S&P CVKD unavailable / 7.68% |
LoseCVKD / S&P CVKD unavailable / 12.46% |
| 2017-Q40/3 |
LoseCVKD / S&P CVKD unavailable / 6.64% |
LoseCVKD / S&P CVKD unavailable / 7.03% |
LoseCVKD / S&P CVKD unavailable / 13.82% |
| 2017-Q30/3 |
LoseCVKD / S&P CVKD unavailable / 4.48% |
LoseCVKD / S&P CVKD unavailable / 5.68% |
LoseCVKD / S&P CVKD unavailable / 17.57% |
| 2017-Q20/3 |
LoseCVKD / S&P CVKD unavailable / 3.09% |
LoseCVKD / S&P CVKD unavailable / 4.83% |
LoseCVKD / S&P CVKD unavailable / 17.74% |
| 2017-Q10/3 |
LoseCVKD / S&P CVKD unavailable / 6.07% |
LoseCVKD / S&P CVKD unavailable / 3.67% |
LoseCVKD / S&P CVKD unavailable / 13.32% |
| 2016-Q40/3 |
LoseCVKD / S&P CVKD unavailable / 3.82% |
LoseCVKD / S&P CVKD unavailable / 2.09% |
LoseCVKD / S&P CVKD unavailable / 7.05% |
| 2016-Q30/3 |
LoseCVKD / S&P CVKD unavailable / 3.85% |
LoseCVKD / S&P CVKD unavailable / 0.20% |
LoseCVKD / S&P CVKD unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CVKD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -87.92% | 20.78% |
| Annualized return | -87.92% | 20.78% |
5Y · 2023-01-20 to 2026-08-27
| Metric | CVKD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.47% | 83.14% |
| Annualized return | -52.06% | 12.86% |
10Y · 2023-01-20 to 2026-08-27
| Metric | CVKD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.47% | 319.30% |
| Annualized return | -30.76% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |